In order to expand the cancer immunotherapy pipeline, Boehringer Ingelheim launched another acquisition

Recently, Boehringer Ingelheim announced the acquisition of Abexxa Biologics, a biopharmaceutical company
.
For this acquisition, Boehringer Ingelheim said it will be able to use Abexxa's expertise in targeting cancer-specific proteins inside cells (not expressed on cell membranes) to expand the range of potential cancer antigen targets
.
Among them, Abexxa's technology in particular may promote the development of cancer immunotherapy, and these therapies will be effective for a wider range of patients and cancer types
.
It is understood that immunotherapy is a concept of using the immune system to treat diseases, and also using the immune system to treat diseases.
Generally speaking, it is a relatively large treatment system, which is also involved in tumor occurrence, development, metastasis, reversal, and regression.
Occupy an important position
.
At present, cancer immunotherapy has become the mainstay of cancer treatment together with surgery, chemotherapy, radiotherapy, and targeted therapy
.
Statistics show that the pipeline of cancer immunotherapy (IO) therapy has continued to expand in the past two years.
The total number of therapies has expanded from 2030 two years ago to 3876, an increase of 91%
.
At the same time, cell therapy is growing very fast, and 797 new therapies have appeared in the past two years
.
On the whole, the field of cancer immunotherapy is a field with rapid progress and continuous innovation
.
It is attracting more and more pharmaceutical companies and research institutions to join, and is committed to transforming scientific innovations into anti-cancer drugs that change the treatment model
.
In fact, Boehringer Ingelheim is one of the pharmaceutical companies that are very concerned about cancer immunotherapy
.
In addition to this acquisition, as early as this year, Boehringer Ingelheim and Enara Bio announced that they have reached a strategic cooperation and licensing agreement to research and develop new targeted cancer immunotherapies by using Enara Bio's Dark Antigen discovery platform
.
According to the agreement, Enara Bio will then be eligible to receive an advance payment, as well as research/preclinical milestone payments and licensing fees for each tumor type studied
.
Of course, in addition to royalties for future product sales, Enara Bio is also eligible to receive more than 876 million euros in clinical, registration and commercialization milestone payments
.
In fact, the above transaction is only a small part of Boehringer Ingelheim's series of strategic acquisitions and cooperation
.
The author understands that Boehringer Ingelheim has been increasing R&D investment substantially in recent years, aiming to develop innovative drugs and therapies for diseases that cannot be effectively treated
.
It is reported that in 2020, Boehringer Ingelheim's total R&D expenditure has reached 3.
7 billion euros, a year-on-year increase of 7%
.
The analysis believes that these acquisitions and cooperation will continue to strengthen Boehringer Ingelheim's overall tumor strategy in the future, and combine cancer immunity and cancer cell targeted therapies to fight cancer
.
In addition, the industry expects that Boehringer Ingelheim will have more market advantages and strong capabilities through this strategy, and will further strengthen its position in the oncology field while developing more innovative cancer immunity Therapies to accelerate the realization of next-generation cancer treatments
.